Q-TWiST analysis of pembrolizumab combined with chemotherapy as first-line treatment of metastatic TNBC that expresses PD-L1

被引：0
|
作者：
Fasching, P. A. [1 ]
Huang, M. [2 ]
Haiderali, A. [3 ]
Pan, W. [4 ]
Hu, P. [2 ]
Chaudhuri, M. [5 ]
De Tilleghem, C. Le Bailly [6 ]
Cappoen, N. [6 ]
O'Shaughnessy, J. [7 ]
机构：
[1] Univ Hosp Erlangen, Dept Gynecol & Obstet, Comprehens Canc Ctr Erlangen EMN, Erlangen, Germany
[2] Merck & Co Inc, Econ & Data Sci, MRL Labs, Upper Gwynedd Campus, N Wales, PA USA
[3] Merck & Co Inc, Ctr Observat & Real World Evidence, Corp Headquarters, Kenilworth, NJ USA
[4] Merck & Co Inc, Oncol Dept, Rahway, NJ 07065 USA
[5] CHEORS Complete Hlth Econ Outcomes & Res Solut, Oncol, N Wales, PA USA
[6] HTA Stat Europe MSD, Brussels, Belgium
[7] Baylor Univ, Med Ctr, Texas Oncol, Med Oncol,US Oncol, Dallas, TX USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.03.177
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
159P
引用
收藏
页码：S192 / S193
页数：2
相关论文
共 50 条
  • [1] Q-TWiST analysis of pembrolizumab combined with chemotherapy as first-line treatment of metastatic triple-negative breast cancer that expresses PD-L1
    Huang, Min
    O'Shaughnessy, Joyce
    Haiderali, Amin
    Pan, Wilbur
    Hu, Peter
    Chaudhuri, Mitashri
    De Tilleghem, Celine Le Bailly
    Cappoen, Nicolas
    Fasching, Peter A.
    EUROPEAN JOURNAL OF CANCER, 2022, 177 : 45 - 52
  • [2] COST EFFECTIVENESS OF PEMBROLIZUMAB COMBINED WITH CHEMOTHERAPY VS. CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR METASTATIC TNBC THAT EXPRESSES PD-L1 IN THE UNITED STATES
    Huang, M.
    Fasching, P.
    Haiderali, A.
    Pan, W.
    Gray, E.
    Zhou, J.
    Hu, P. H.
    De Tilleghem, Le Bailly C.
    Cappoen, N.
    Chaudhuri, M.
    O'Shaughnessy, J.
    VALUE IN HEALTH, 2022, 25 (07) : S365 - S365
  • [3] Q-TWiST analysis for pembrolizumab plus chemotherapy versus chemotherapy as first-line treatment for patients with advanced esophageal cancer in the KEYNOTE-590 study
    Diez Garcia, M.
    Shah, S.
    Joo, S.
    Valderrama, A.
    Zhang, S.
    Zhang, Y.
    Enzinger, P.
    ANNALS OF ONCOLOGY, 2022, 33 : S348 - S348
  • [4] Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC
    Wan, Ning
    Zhang, Tian-tian
    Hua, Si-hua
    Lu, Zi-luo
    Ji, Bo
    Li, Li-xia
    Lu, Li-qing
    Huang, Wen-jie
    Jiang, Jie
    Li, Jian
    CANCER MEDICINE, 2020, 9 (05): : 1683 - 1693
  • [5] Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States
    Huang, Min
    Lou, Yanyan
    Pellissier, James
    Burke, Thomas
    Liu, Frank Xiaoqing
    Xu, Ruifeng
    Velcheti, Vamsidhar
    PHARMACOECONOMICS, 2017, 35 (08) : 831 - 844
  • [6] Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States
    Min Huang
    Yanyan Lou
    James Pellissier
    Thomas Burke
    Frank Xiaoqing Liu
    Ruifeng Xu
    Vamsidhar Velcheti
    PharmacoEconomics, 2017, 35 : 831 - 844
  • [7] Q-TWiST Analysis to Assess Benefit–Risk of Pembrolizumab in Patients with PD-L1–Positive Advanced or Metastatic Non-small Cell Lung Cancer
    Min Huang
    M. Catherine Pietanza
    Ayman Samkari
    James Pellissier
    Thomas Burke
    Sheenu Chandwani
    Fansen Kong
    A. Simon Pickard
    PharmacoEconomics, 2019, 37 : 105 - 116
  • [8] COST-EFFECTIVENESS OF PEMBROLIZUMAB IN FIRST-LINE TREATMENT OF PD-L1 POSITIVE PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER
    Nedzesky, J.
    Veenstra, D.
    VALUE IN HEALTH, 2022, 25 (07) : S343 - S343
  • [9] Q-TWiST analysis to assess benefit-risk of pembrolizumab in patients with PD-L1-positive advanced or metastatic NSCLC
    Huang, M.
    Pietanza, M. C.
    Samkari, A.
    Pellissier, J.
    Burke, T.
    Chandwani, S.
    Kong, F.
    Pickard, A. S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [10] First-Line Pembrolizumab With or Without Chemotherapy in PD-L1 positive NSCLC: A Network Meta-Analysis of Randomized Trials
    Doherty, M.
    Delos Santos, S.
    Rahmadian, A. Putri
    Chan, K.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S465 - S466
12345